Deaths from SUD are increasing, rising from approximately 284,000 deaths in 2007 to 352,000 in 2017, creating a global health threat (6)
Ecotoxicol Environ Saf (2020) 191:110236
Biochem Pharmacol 202:115141
Disclosures: Chanda Ho: Nothing to Disclose, Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Aly Cortella: Nothing to Disclose, Alison Canchola: Nothing to Disclose, Pushkar Inamdar: Nothing to Disclose, Pragati Kenkare: Nothing to Disclose, Jane Vu: Nothing to Disclose, Sixiang Nie: Nothing to Disclose, Ma Somsouk: Nothing to Disclose, Michele Tana: Nothing to Disclose, Caroline Thompson: Nothing to Disclose, Scarlett Gomez: Nothing to Disclose, Hashem El-Serag: Nothing to Disclose, Miok Kim: Nothing to Disclose, Mark Segal: Nothing to Disclose, Yihe Daida: Vir Biotechnology: Grant/Research Support, Sanofi: Grant/Research Support, GSK: Grant/Research Support, Su-Ying Liang: Nothing to Disclose, Mindy Hebert-Derouen: Nothing to Disclose, Salma Shariff-Marco: Nothing to Disclose 934 SAFETY AND EFFICACY OF CONTRACEPTIVE AGENTS AFTER LIVER TRANSPLANTATION Grace Zhang 1 Cynthia Fenton 2 Dominika Seidman 3 Elle Oberweis-Manion 3 Monika Sarkar 1 , 1 University of California, San Francisco, 2 University of California San Franscisco, 3 University of California San Francisco Background: The number of reproductive-aged liver transplant (LT) recipients is rising, and fertility is rapidly restored in the post-operative setting
This is why licensed 503A compounding pharmacies formulate tirzepatide with stabilizing buffers and preservatives to protect both receptor-binding sites
